All In Biotech

Drug Trial Radar · NCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

452

Actual

Start

Jun 3, 2020

Primary completion

May 4, 2027

Study completion May 4, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
May 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-expressing gastric, GEJ and esophageal cancer patients who have not received prior treatment for advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the potential to become a therapeutic option for this patient population.

Conditions

  • Gastric Cancer

Interventions

  • Fluorouracil (5-FU)Drug

    5-FU: administered as an IV infusion

  • CapecitabineDrug

    Capecitabine: administered orally

  • DurvalumabBiological

    Durvalumab: administered as an IV infusion

  • OxaliplatinDrug

    Oxaliplatin: administered as an IV infusion

  • TrastuzumabBiological

    Trastuzumab: administered as an IV infusion

  • Trastuzumab deruxtecanDrug

    T-DXd: administered as an IV infusion

  • CisplatinDrug

    Cisplatin: administered as an IV infusion

  • PembrolizumabBiological

    Pembrolizumab: administered as an IV infusion

  • VolrustomigBiological

    Volrustomig: administered as an IV infusion

  • RilvegostomigBiological

    Rilvegostomig: administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
  2. Part 1: Ocurrence of dose-limiting toxicities (DLTs)Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
  3. Part 1: Changes from baseline in laboratory parametersTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
  4. Part 1: Changes from baseline in vital signsTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
  5. Part 1: Changes from baseline in electrocardiogram (ECG) resultsTime frame: Safety will be assessed up to the follow-up period, approximately 24 months.
  6. Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)Time frame: (Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months

Locations

71 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    New York, New York

  • Research Site

    Houston, Texas

  • Research Site

    Londrina, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    Santa Maria, Brazil

  • Research Site

    São Jose Do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Wuhan, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Frankfurt, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Mannheim, Germany

  • Research Site

    München, Germany

  • Research Site

    Milan, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Padova, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Verona, Italy

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Utrecht, Netherlands

  • Research Site

    Gdansk, Poland

  • Research Site

    Konin, Poland

  • Research Site

    Koszalin, Poland

  • Research Site

    Krakow, Poland

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.